Aardvark Therapeutics Inc (AARD) Stock News

Rosen Law Firm announces a securities class action lawsuit against Aardvark Therapeutics, Inc. for allegedly making materially false and misleading statements regarding the safety and prospects of its drug ARD-101. Investors who purchased securities during the IPO on February 13, 2025 or between February 13, 2025 and May 14, 2026 may be eligible to join the class action. The deadline to serve as lead plaintiff is October 13, 2026.

Grabar Law Office is investigating securities fraud and fiduciary duty breach claims against four companies: Aardvark Therapeutics for allegedly misrepresenting the safety profile of its drug candidate ARD-101 before a clinical hold was placed; Coastal Financial Corporation for failing to disclose deterioration in its CCBX partner loan portfolio and credit losses; Erasca, Inc. for making misleading statements about its ERAS-0015 therapy and improper comparisons to competitors; and New Era Energy & Digital for overstating progress on its data center project and allegedly engaging in fraudulent oil-and-gas schemes.

Rosen Law Firm announces a securities class action lawsuit against Aardvark Therapeutics, with an October 13, 2026 deadline for investors to serve as lead plaintiff. The lawsuit alleges that defendants made materially false and misleading statements regarding the safety and prospects of their drug candidate ARD-101, causing investor damages when the true details emerged.

Rosen Law Firm has announced multiple securities class action lawsuits against Aardvark Therapeutics, FuelCell Energy, and XTI Aerospace. The primary case involves Aardvark Therapeutics, where investors claim the company made materially false statements about the safety and prospects of its ARD-101 drug candidate in its IPO registration statement and throughout the class period. Investors have until October 13, 2026 to become lead plaintiffs in the Aardvark case.

Rosen Law Firm is reminding investors in Aardvark Therapeutics, Inc. (AARD) of an October 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the safety and prospects of its drug ARD-101, causing investor damages when the truth entered the market. The firm is also investigating claims related to Hyliion Holdings Corp. (HYLN) and FLOW cryptocurrency.

The Rosen Law Firm announced a securities class action lawsuit against Aardvark Therapeutics, Inc. (AARD) for allegedly making false and misleading statements regarding the safety profile of its drug ARD-101 and overstating its clinical, regulatory, and commercial prospects. The lawsuit covers investors who purchased securities between February 13, 2025 (IPO date) and May 14, 2026. The deadline to file a claim is October 13, 2026.

Aardvark Therapeutics faces a securities fraud class action lawsuit covering the period February 10, 2025 to May 14, 2026. The company voluntarily paused its Phase 3 HERO trial in February 2026 due to cardiac safety concerns, causing a 56.2% stock decline. In May 2026, the FDA placed a full clinical hold on the drug ARD-101, resulting in a further 32.1% stock drop. Investors who suffered losses are urged to file lead plaintiff motions by October 13, 2026.

Rosen Law Firm is reminding investors in Aardvark Therapeutics (AARD), UWM Holdings (UWMC), and ARS Pharmaceuticals (SPRY) of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made materially false statements and failed to disclose material adverse facts about their businesses, with Aardvark specifically accused of overstating the safety and commercial prospects of its ARD-101 drug candidate.

Law firm Lowey Dannenberg is investigating Aardvark Therapeutics for potential federal securities violations related to its lead drug ARD-101. The company paused its Phase 3 trial in February 2026 due to cardiac safety concerns and faced an FDA clinical hold in May 2026, causing significant stock price declines and shareholder losses.

Rosen Law Firm is urging investors in Aardvark Therapeutics (AARD) to join a securities class action lawsuit with an October 13, 2026 deadline for lead plaintiff claims. The lawsuit alleges that defendants made materially false statements about the safety and prospects of their drug ARD-101, and failed to disclose material adverse facts about the company's business and operations.

Aardvark Therapeutics faces a securities fraud class action lawsuit covering the period February 10, 2025 to May 14, 2026. The company voluntarily paused its Phase 3 HERO trial in February 2026 due to cardiac safety concerns, causing a 56.2% stock decline. In May 2026, the FDA placed a full clinical hold on the drug ARD-101, resulting in a further 32.1% stock drop. Investors who suffered losses are urged to file lead plaintiff motions by October 13, 2026.

Rosen Law Firm is urging investors who purchased Aardvark Therapeutics securities during its IPO on February 13, 2025 or between February 13, 2025 and May 14, 2026 to join a securities class action lawsuit. The lawsuit alleges that defendants made materially false and misleading statements about the safety and prospects of ARD-101, with an October 13, 2026 deadline to serve as lead plaintiff.

Aardvark Therapeutics faces a securities fraud class action lawsuit covering the period February 10, 2025 to May 14, 2026. The company voluntarily paused its Phase 3 HERO trial in February 2026 due to cardiac safety concerns, causing a 56.2% stock decline. In May 2026, the FDA placed a full clinical hold on the drug ARD-101, resulting in a further 32.1% stock drop. Investors are urged to file lead plaintiff motions by October 13, 2026.

Rosen Law Firm is reminding investors in Aardvark Therapeutics, Inc. of an October 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the safety and prospects of its drug ARD-101, and failed to disclose material adverse facts about the company's business and operations.

Grabar Law Office announced investigations into shareholder claims against four companies: Aardvark Therapeutics for allegedly misleading statements about drug safety leading to 56% stock decline; Flotek Industries for misrepresentations regarding a terminated Puerto Rico power project; GoDaddy for failing to disclose impact of promotional pricing on bookings; and Hub Group for material financial statement misstatements. Long-term shareholders may pursue corporate reforms and compensation.

Hagens Berman has filed a securities class action lawsuit against Aardvark Therapeutics, alleging the company made materially false statements about the safety of its lead drug candidate ARD-101. The lawsuit covers investors who purchased stock during the IPO on February 13, 2025, through May 14, 2026. Aardvark voluntarily paused its Phase 3 HERO trial in February 2026 after discovering reversible cardiac observations, causing a 56% stock decline. The FDA subsequently placed a full clinical hold on ARD-101 in May 2026, resulting in an additional 32.1% stock drop. The lead plaintiff deadline is October 13, 2026.

Pomerantz LLP is investigating potential securities fraud claims against Aardvark Therapeutics following the company's voluntary pause of its Phase 3 HERO trial in February 2026 due to cardiac safety concerns, and a subsequent FDA clinical hold placed on its ARD-101 drug in May 2026. The stock declined 56.2% following the initial announcement and an additional 32.1% after the FDA clinical hold.

Aardvark Therapeutics (AARD) stock plummeted 56% on March 2, 2026, after the company paused its Phase 3 HERO trial for ARD-101 due to serious cardiac safety concerns. The abrupt halt contradicts prior investor assurances about the drug's safety profile, prompting Hagens Berman to investigate potential securities law violations and misleading disclosures about the drug's development and FDA communications.